vs
DOCUSIGN, INC.（DOCU）与Insulet Corporation（PODD）财务数据对比。点击上方公司名可切换其他公司
DOCUSIGN, INC.的季度营收约是Insulet Corporation的1.1倍（$818.4M vs $761.7M），Insulet Corporation净利率更高（12.0% vs 10.2%，领先1.7%），Insulet Corporation同比增速更快（33.9% vs 8.4%），DOCUSIGN, INC.自由现金流更多（$262.9M vs $89.5M）
DocuSign是总部位于美国加利福尼亚州旧金山的软件企业，为各类机构提供多设备支持的电子协议管理及电子签名相关产品。截至2025年，公司在180个国家拥有约170万客户，其处理的签名符合美国ESIGN法案、欧盟eIDAS法规要求，满足欧盟高级及合格签名标准。
Insulet Corporation是深耕糖尿病治疗领域的医疗器械企业，核心产品为胰岛素泵，通过持续皮下输注胰岛素的疗法为患者给药。其产品通常由泵主体、一次性胰岛素储药仓，以及包含皮下植入套管和连接管路的一次性输注套件构成，满足不同患者的治疗需求。
DOCU vs PODD — 直观对比
营收规模更大
DOCU
是对方的1.1倍
$761.7M
营收增速更快
PODD
高出25.4%
8.4%
净利率更高
PODD
高出1.7%
10.2%
自由现金流更多
DOCU
多$173.4M
$89.5M
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $818.4M | $761.7M |
| 净利润 | $83.7M | $91.1M |
| 毛利率 | 79.2% | 69.5% |
| 营业利润率 | 10.4% | 16.0% |
| 净利率 | 10.2% | 12.0% |
| 营收同比 | 8.4% | 33.9% |
| 净利润同比 | 34.1% | 157.3% |
| 每股收益（稀释后） | $0.40 | $1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCUPODD
| Q1 26 | — | $761.7M | ||
| Q4 25 | $818.4M | $783.7M | ||
| Q3 25 | $800.6M | $706.3M | ||
| Q2 25 | $763.7M | $649.1M | ||
| Q1 25 | — | $569.0M | ||
| Q4 24 | — | $597.5M | ||
| Q3 24 | — | $543.9M | ||
| Q2 24 | — | $488.5M |
净利润DOCUPODD
| Q1 26 | — | $91.1M | ||
| Q4 25 | $83.7M | $101.6M | ||
| Q3 25 | $63.0M | $87.6M | ||
| Q2 25 | $72.1M | $22.5M | ||
| Q1 25 | — | $35.4M | ||
| Q4 24 | — | $100.7M | ||
| Q3 24 | — | $77.5M | ||
| Q2 24 | — | $188.6M |
毛利率DOCUPODD
| Q1 26 | — | 69.5% | ||
| Q4 25 | 79.2% | 72.6% | ||
| Q3 25 | 79.3% | 72.2% | ||
| Q2 25 | 79.4% | 69.7% | ||
| Q1 25 | — | 71.9% | ||
| Q4 24 | — | 72.1% | ||
| Q3 24 | — | 69.3% | ||
| Q2 24 | — | 67.7% |
营业利润率DOCUPODD
| Q1 26 | — | 16.0% | ||
| Q4 25 | 10.4% | 18.7% | ||
| Q3 25 | 8.1% | 16.7% | ||
| Q2 25 | 7.9% | 18.7% | ||
| Q1 25 | — | 15.6% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | — | 16.2% | ||
| Q2 24 | — | 11.2% |
净利率DOCUPODD
| Q1 26 | — | 12.0% | ||
| Q4 25 | 10.2% | 13.0% | ||
| Q3 25 | 7.9% | 12.4% | ||
| Q2 25 | 9.4% | 3.5% | ||
| Q1 25 | — | 6.2% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | — | 14.2% | ||
| Q2 24 | — | 38.6% |
每股收益（稀释后）DOCUPODD
| Q1 26 | — | $1.30 | ||
| Q4 25 | $0.40 | $1.42 | ||
| Q3 25 | $0.30 | $1.24 | ||
| Q2 25 | $0.34 | $0.32 | ||
| Q1 25 | — | $0.50 | ||
| Q4 24 | — | $1.38 | ||
| Q3 24 | — | $1.08 | ||
| Q2 24 | — | $2.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $583.3M | $480.4M |
| 总债务越低越好 | — | $18.6M |
| 股东权益账面价值 | $2.0B | $1.3B |
| 总资产 | $4.0B | $3.0B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资DOCUPODD
| Q1 26 | — | $480.4M | ||
| Q4 25 | $583.3M | — | ||
| Q3 25 | $600.0M | — | ||
| Q2 25 | $657.4M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
总债务DOCUPODD
| Q1 26 | — | $18.6M | ||
| Q4 25 | — | $930.8M | ||
| Q3 25 | — | $934.9M | ||
| Q2 25 | — | $939.0M | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B |
股东权益DOCUPODD
| Q1 26 | — | $1.3B | ||
| Q4 25 | $2.0B | $1.5B | ||
| Q3 25 | $2.0B | $1.4B | ||
| Q2 25 | $2.0B | $1.5B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $998.4M |
总资产DOCUPODD
| Q1 26 | — | $3.0B | ||
| Q4 25 | $4.0B | $3.2B | ||
| Q3 25 | $3.9B | $3.0B | ||
| Q2 25 | $3.9B | $3.5B | ||
| Q1 25 | — | $3.5B | ||
| Q4 24 | — | $3.1B | ||
| Q3 24 | — | $3.0B | ||
| Q2 24 | — | $2.9B |
负债/权益比DOCUPODD
| Q1 26 | — | 0.01× | ||
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.68× | ||
| Q2 25 | — | 0.64× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.36× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $290.3M | $113.8M |
| 自由现金流经营现金流 - 资本支出 | $262.9M | $89.5M |
| 自由现金流率自由现金流/营收 | 32.1% | 11.8% |
| 资本支出强度资本支出/营收 | 3.3% | 3.2% |
| 现金转化率经营现金流/净利润 | 3.47× | 1.25× |
| 过去12个月自由现金流最近4个季度 | — | $415.7M |
8季度趋势，按日历期对齐
经营现金流DOCUPODD
| Q1 26 | — | $113.8M | ||
| Q4 25 | $290.3M | $183.3M | ||
| Q3 25 | $246.1M | $125.7M | ||
| Q2 25 | $251.4M | $196.5M | ||
| Q1 25 | — | $63.8M | ||
| Q4 24 | — | $147.7M | ||
| Q3 24 | — | $98.5M | ||
| Q2 24 | — | $96.5M |
自由现金流DOCUPODD
| Q1 26 | — | $89.5M | ||
| Q4 25 | $262.9M | $48.2M | ||
| Q3 25 | $217.6M | $100.1M | ||
| Q2 25 | $227.8M | $177.9M | ||
| Q1 25 | — | $51.5M | ||
| Q4 24 | — | $94.1M | ||
| Q3 24 | — | $71.8M | ||
| Q2 24 | — | $74.0M |
自由现金流率DOCUPODD
| Q1 26 | — | 11.8% | ||
| Q4 25 | 32.1% | 6.2% | ||
| Q3 25 | 27.2% | 14.2% | ||
| Q2 25 | 29.8% | 27.4% | ||
| Q1 25 | — | 9.1% | ||
| Q4 24 | — | 15.7% | ||
| Q3 24 | — | 13.2% | ||
| Q2 24 | — | 15.1% |
资本支出强度DOCUPODD
| Q1 26 | — | 3.2% | ||
| Q4 25 | 3.3% | 17.2% | ||
| Q3 25 | 3.6% | 3.6% | ||
| Q2 25 | 3.1% | 2.9% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 9.0% | ||
| Q3 24 | — | 4.9% | ||
| Q2 24 | — | 4.6% |
现金转化率DOCUPODD
| Q1 26 | — | 1.25× | ||
| Q4 25 | 3.47× | 1.80× | ||
| Q3 25 | 3.91× | 1.43× | ||
| Q2 25 | 3.49× | 8.73× | ||
| Q1 25 | — | 1.80× | ||
| Q4 24 | — | 1.47× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | 0.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOCU
| Subscription And Circulation | $801.0M | 98% |
| Professional Services And Other | $17.4M | 2% |
PODD
| Omnipod | $515.6M | 68% |
| International Omnipod | $242.9M | 32% |
| Drug Delivery | $3.3M | 0% |
